Vaxxinity, Inc. (Nasdaq: VAXX), today announced that the first patient with Parkinson’s disease (PD) has been dosed with UB-312 in Part B of a double-blinded, placebo-controlled Phase 1 clinical trial, following completion of Part A of the Phase 1 trial in healthy volunteers.
January 12, 2022
· 5 min read